Federal Circuit affirms tribal sovereign immunity cannot be asserted in IPRs
Allergan is not protected from PTAB review by the Saint Regis Mohawk Tribe’s sovereign immunity, says the appeals court in a ruling that relies on the Supreme Court’s FMC opinion
The Federal Circuit has affirmed the Patent Trial and Appeal Board (PTAB) refusal to terminate inter partes review (IPR) proceedings against Allergan patents for dry eye treatment Restasis. The drug company controversially transferred its patents to a Native American tribe...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.